The site uses anonymous third party analytic cookies: in accessing any element/area of the site outside of this banner, you consent to receiving cookies.

Knowledge Hub

Here you will find a selection of our latest articles, reports, white papers and webcasts from our Consultancy Team.

What does integration mean for NHS-Industry partnership?

Johnny Skillicorn-Aston and James Roach of Conclusio look at what this means for Pharma and the NHS Conclusio has a long-held the view that...

Building trust in the Covid-19 recovery era

Simon Grime of Wilmington Healthcare, explores how pharma can strengthen existing relationships and form new ones in an NHS customer environment that...

How to embrace digital engagement, intelligently

By Simon Grime, Director - Digital Engagement, Wilmington Healthcare Covid has changed the landscape for customer engagement so now it’s time to...

Integrated NHS finances: what do they mean for High Cost Drugs?

Oli Hudson and Steve How, of Wilmington Healthcare, explore NHS England’s new system-level funding and its impact on prescribing for High Cost...

Covid-19: How is it affecting prescribing patterns?

Oli Hudson, Content Director at Wilmington Healthcare, analyses prescribing data in three key disease areas In common with many other aspects of...

Covid, service change and the NHS Reset: Just how can industry keep up?

In this on-demand article, first published in November 2020, Oli Hudson, Content Director at Wilmington Healthcare, looks at the current onslaught of...

How can pharma align its brand strategy with the NHS Reset?

Oli Hudson, of Wilmington Healthcare, explores how pharma should respond to plans to ‘reboot’ the NHS during the covid recovery era There is a...

Covid-19 redefines rules of customer engagement

Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs Covid-19 has...

Covid-19: how is it impacting on the NHS Long-term Plan?

Oli Hudson and Paul Midgley, of Wilmington Healthcare, explain how coronavirus has expedited some parts of the plan but put others in...

Covid-19: what could it mean for the diabetic population?

Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it On March 28,...

Mapping the intricate oncology landscape

Simon Grime, of Wilmington Healthcare, explains how data and intelligence tools help pharma deliver tailored engagement programmes to diverse...

GIRFT: Can ophthalmology point to where other NHS areas are heading?

Oli Hudson, Content Director at Wilmington Healthcare, looks at the latest GIRFT report and sees what lessons it holds for the MedTech industry at...

What next for biosimilars?

James Roach, Director at West Essex ICP, looks at the future for biosimilar medicines, surveys a future landscape where medicines management will be...

The Value Exchange

Simon Grime, of Wilmington Healthcare, explains the principles of exchanging value with customers to gain trust and consent Today in B2B...

Latest Tweets from @Wilmhealthcare